AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance

U.S. Markets closed

AstraZeneca PLC (AZN)

NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
25.82-0.07 (-0.27%)
At close: 4:02 PM EST

25.98 0.16 (0.62%)
After hours: 5:18 PM EST

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close25.89
Bid25.66 x 100
Ask25.85 x 100
Day's Range25.68 - 26.04
52 Week Range25.68 - 35.04
Avg. Volume6,219,393
Market Cap67.21B
PE Ratio (TTM)26.50
Earnings DateN/A
Dividend & Yield0.90 (3.48%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.7 hours ago

    FitBit, Teva Slide into Monday’s 52-Week Low Club

    December 2, 2016: Here are four stocks trading with relatively heavy volume among 42 equities making new 52-week lows in Monday’s session. On the NYSE, advancers led decliners by about 2.5 to 1 and on ...

  • Is Diageo plc (ADR) (DEO) A Good Stock To Buy?
    Insider Monkey10 hours ago

    Is Diageo plc (ADR) (DEO) A Good Stock To Buy?

    You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund investors like Carl Icahn and George […]

  • Business Wire10 hours ago

    Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic Leukemia

    AstraZeneca and its hematology Center of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat forms of chronic lymphocytic leukemia , the most common type of leukemia in adults.1 The trial includes data from individuals with intolerance to ibrutinib and those with Richter transformation, ...